PHOENIX — Azithromycin failed to prevent infants with severe respiratory syncytial virus, or RSV, from later developing recurrent wheeze, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“About half of infants admitted to a hospital with RSV will be diagnosed with asthma by age 7,” Avraham Beigelman, MD, associate professor of pediatrics and a pediatric allergist and immunologist in the division of allergy and pulmonary medicine in the department of pediatrics at Washington University School of Medicine in St. Louis, said